Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Non-Current Debt (2024 - 2025)

Historic Non-Current Debt for Precision Biosciences (DTIL) over the last 2 years, with Q3 2025 value amounting to $22.4 million.

  • Precision Biosciences' Non-Current Debt rose 43.09% to $22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.4 million, marking a year-over-year increase of 43.09%. This contributed to the annual value of $22.3 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Precision Biosciences reported Non-Current Debt of $22.4 million as of Q3 2025, which was up 43.09% from $22.4 million recorded in Q2 2025.
  • Precision Biosciences' 5-year Non-Current Debt high stood at $22.4 million for Q3 2025, and its period low was $22.3 million during Q3 2024.